{"id":71725,"date":"2026-04-15T13:45:20","date_gmt":"2026-04-15T08:15:20","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=71725"},"modified":"2026-04-15T13:45:23","modified_gmt":"2026-04-15T08:15:23","slug":"mankind-pharma-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/","title":{"rendered":"Mankind Pharma Share Price Target 2026: Analyst Forecast, Bull &amp; Bear Case"},"content":{"rendered":"<p><strong>Mankind Pharma<\/strong> (NSE: MANKIND) trades at Rs 1,850 as of April 2026 \u2014 against a 52-week high of Rs 2,800 and a 52-week low of Rs 1,650. The analyst consensus 12-month Mankind Pharma share price target is Rs 2,200\u20132,500, implying 19\u201335% upside. This article covers the key catalysts, risks, financial positioning, and a structured bull\/bear case share price target for 2026 and beyond.<\/p><p>Get free SEBI-registered analyst research on <strong>Mankind Pharma<\/strong> on <a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Univest<\/strong><\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Mankind_Pharma_Share_Price_%E2%80%94_Snapshot\" title=\"Mankind Pharma Share Price \u2014 Snapshot\">Mankind Pharma Share Price \u2014 Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#About_Mankind_Pharma\" title=\"About Mankind Pharma\">About Mankind Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Key_Growth_Catalysts_%E2%80%94_Mankind_Pharma_Share_Price_Target\" title=\"Key Growth Catalysts \u2014 Mankind Pharma Share Price Target\">Key Growth Catalysts \u2014 Mankind Pharma Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#1_BSV_Group_Acquisition_Synergies\" title=\"1. BSV Group Acquisition Synergies\">1. BSV Group Acquisition Synergies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#2_Consumer_OTC_Brand_Portfolio\" title=\"2. Consumer OTC Brand Portfolio\">2. Consumer OTC Brand Portfolio<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#3_India_Branded_Generic_Volume_Growth\" title=\"3. India Branded Generic Volume Growth\">3. India Branded Generic Volume Growth<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Key_Risks_to_Watch\" title=\"Key Risks to Watch\">Key Risks to Watch<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Risk_1_Integration_of_Rs_13600_Cr_BSV_acquisition_above_market_expectations\" title=\"Risk 1: Integration of Rs 13,600 Cr BSV acquisition above market expectations\">Risk 1: Integration of Rs 13,600 Cr BSV acquisition above market expectations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Risk_2_Promoter_sell-down_creating_supply_overhang_perception\" title=\"Risk 2: Promoter sell-down creating supply overhang perception\">Risk 2: Promoter sell-down creating supply overhang perception<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Mankind_Pharma_Share_Price_Target_2026\" title=\"Mankind Pharma Share Price Target 2026\">Mankind Pharma Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Short-Term_Target_3%E2%80%936_Months\" title=\"Short-Term Target (3\u20136 Months)\">Short-Term Target (3\u20136 Months)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#12-Month_Analyst_Consensus_Target\" title=\"12-Month Analyst Consensus Target\">12-Month Analyst Consensus Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Long-Term_Target_FY27%E2%80%93FY28\" title=\"Long-Term Target (FY27\u2013FY28)\">Long-Term Target (FY27\u2013FY28)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Q_What_is_Mankind_Pharma_share_price_target_for_2026\" title=\"Q: What is Mankind Pharma share price target for 2026?\">Q: What is Mankind Pharma share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Q_What_is_Mankind_Pharmas_current_share_price\" title=\"Q: What is Mankind Pharma&#8217;s current share price?\">Q: What is Mankind Pharma&#8217;s current share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Q_Is_Mankind_Pharma_a_good_buy_at_current_levels\" title=\"Q: Is Mankind Pharma a good buy at current levels?\">Q: Is Mankind Pharma a good buy at current levels?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Q_What_are_the_key_risks_for_Mankind_Pharma\" title=\"Q: What are the key risks for Mankind Pharma?\">Q: What are the key risks for Mankind Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Q_What_is_Mankind_Pharmas_market_cap_and_PE\" title=\"Q: What is Mankind Pharma&#8217;s market cap and P\/E?\">Q: What is Mankind Pharma&#8217;s market cap and P\/E?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Q_What_are_Mankind_Pharmas_growth_catalysts\" title=\"Q: What are Mankind Pharma&#8217;s growth catalysts?\">Q: What are Mankind Pharma&#8217;s growth catalysts?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Q_What_is_Mankind_Pharmas_long-term_target\" title=\"Q: What is Mankind Pharma&#8217;s long-term target?\">Q: What is Mankind Pharma&#8217;s long-term target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Q_Where_can_I_track_Mankind_Pharma_live\" title=\"Q: Where can I track Mankind Pharma live?\">Q: Where can I track Mankind Pharma live?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-2026\/#Recent_Articles\" title=\"Recent Articles\">Recent Articles<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Mankind_Pharma_Share_Price_%E2%80%94_Snapshot\"><\/span><strong>Mankind Pharma Share Price \u2014 Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Parameter<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>CMP (April 2026)<\/td><td>Rs 1,850<\/td><\/tr><tr><td>52-Week High<\/td><td>Rs 2,800<\/td><\/tr><tr><td>52-Week Low<\/td><td>Rs 1,650<\/td><\/tr><tr><td>Market Cap<\/td><td>Rs 74,000 Cr<\/td><\/tr><tr><td>Trailing P\/E<\/td><td>42x<\/td><\/tr><tr><td>NSE Ticker<\/td><td>MANKIND<\/td><\/tr><tr><td>Sector<\/td><td>Pharma \/ Consumer Health \/ OTC<\/td><\/tr><tr><td>12M Analyst Target<\/td><td>Rs 2,200\u20132,500<\/td><\/tr><tr><td>Bull Case<\/td><td>Rs 3,000<\/td><\/tr><tr><td>Bear Case<\/td><td>Rs 1,400<\/td><\/tr><tr><td>Upside (12M)<\/td><td>19\u201335%<\/td><\/tr><\/tbody><\/table><\/figure><p>Track <strong>Mankind Pharma<\/strong> live on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a> \u2014 fundamentals, FII\/DII flows, analyst ratings.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Mankind_Pharma\"><\/span><strong>About Mankind Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here \u2014 Get Free Investment Predictions on Univest<\/strong><\/a>.<\/p><p>Mankind Pharma is India&#8217;s fourth-largest pharma company by volume \u2014 and the most successful brand-builder in Indian OTC health. Prega News (pregnancy test), Gas-O-Fast, Unwanted-72, and AcneStar are dominant brands in their categories.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Growth_Catalysts_%E2%80%94_Mankind_Pharma_Share_Price_Target\"><\/span><strong>Key Growth Catalysts \u2014 Mankind Pharma Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Tap to Access Best Research Pieces on Univest<\/strong><\/a>.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_BSV_Group_Acquisition_Synergies\"><\/span><strong>1. BSV Group Acquisition Synergies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>BSV Group Acquisition Synergies \u2014 Women&#8217;s Health and Critical Care<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Consumer_OTC_Brand_Portfolio\"><\/span><strong>2. Consumer OTC Brand Portfolio<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Consumer OTC Brand Portfolio \u2014 Prega News 72% Market Share<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_India_Branded_Generic_Volume_Growth\"><\/span><strong>3. India Branded Generic Volume Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>India Branded Generic Volume Growth \u2014 Field Force Expansion<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Risks_to_Watch\"><\/span><strong>Key Risks to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_1_Integration_of_Rs_13600_Cr_BSV_acquisition_above_market_expectations\"><\/span><strong>Risk 1: Integration of Rs 13,600 Cr BSV acquisition above market expectations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Integration of Rs 13,600 Cr BSV acquisition above market expectations<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_2_Promoter_sell-down_creating_supply_overhang_perception\"><\/span><strong>Risk 2: Promoter sell-down creating supply overhang perception<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Promoter sell-down creating supply overhang perception<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Mankind_Pharma_Share_Price_Target_2026\"><\/span><strong>Mankind Pharma Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Subscribe to Univest Pro<\/strong><\/a> for premium analyst research on Mankind Pharma.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Short-Term_Target_3%E2%80%936_Months\"><\/span><strong>Short-Term Target (3\u20136 Months)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In the near term, Mankind Pharma is expected to trade in the Rs 1,650\u2013Rs 2 range pending Q4 FY26 results and FY27 guidance clarity. The 52-week low of Rs 1,650 is the primary downside reference for position management.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"12-Month_Analyst_Consensus_Target\"><\/span><strong>12-Month Analyst Consensus Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The analyst consensus 12-month Mankind Pharma share price target is Rs 2,200\u20132,500 \u2014 implying 19\u201335% upside from Rs 1,850. This consensus assumes the primary catalysts materialise and macro conditions stabilise. These are analyst projections, not guaranteed returns. Check live targets on the Univest Screener.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Long-Term_Target_FY27%E2%80%93FY28\"><\/span><strong>Long-Term Target (FY27\u2013FY28)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Mankind Pharma long-term target is Rs 3,000 in the bull case for FY27\u201328 \u2014 achievable if earnings delivery is consistent and catalysts accelerate. The bear case of Rs 1,400 represents the risk scenario if primary headwinds persist.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Scenario<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Key Assumption<\/strong><\/td><\/tr><tr><td>Bear<\/td><td>Rs 1,400<\/td><td>Headwinds persist; earnings miss; macro adverse<\/td><\/tr><tr><td>Base (12M)<\/td><td>Rs 2,200\u20132,500<\/td><td>Catalysts deliver; earnings in line; macro stabilises<\/td><\/tr><tr><td>Bull<\/td><td>Rs 3,000<\/td><td>Catalysts accelerate; beat; sector re-rates<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for live Mankind Pharma price and SEBI-registered analyst alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Mankind Pharma at Rs 1,850 offers risk-reward of 19\u201335% to the 12-month analyst consensus of Rs 2,200\u20132,500. The bull case of Rs 3,000 is achievable on full catalyst delivery; the bear case Rs 1,400 is the downside reference. Track Q4 FY26 results and FY27 management guidance as the primary near-term catalysts for validating the Mankind Pharma share price target thesis.<\/p><p>For more stock research, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><p><strong>Disclaimer: <\/strong>This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available data as of April 2026. Investments in securities are subject to market risk. Please consult a SEBI-registered financial advisor before making any investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Mankind_Pharma_share_price_target_for_2026\"><\/span><strong>Q: What is Mankind Pharma share price target for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 12-month analyst consensus Mankind Pharma share price target is Rs 2,200\u20132,500, implying 19\u201335% upside from Rs 1,850. Bull case is Rs 3,000; bear case is Rs 1,400. These are analyst projections, not guaranteed returns.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Mankind_Pharmas_current_share_price\"><\/span><strong>Q: What is Mankind Pharma&#8217;s current share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Mankind Pharma (NSE: MANKIND) trades at Rs 1,850 as of April 2026. 52-week high is Rs 2,800; 52-week low is Rs 1,650. Market cap is Rs 74,000 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Is_Mankind_Pharma_a_good_buy_at_current_levels\"><\/span><strong>Q: Is Mankind Pharma a good buy at current levels?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This article does not constitute investment advice. Mankind Pharma at Rs 1,850 has an analyst consensus target of Rs 2,200\u20132,500 implying 19\u201335% upside. Review catalysts and risks above and consult a SEBI-registered financial advisor before investing.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_are_the_key_risks_for_Mankind_Pharma\"><\/span><strong>Q: What are the key risks for Mankind Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Primary risks: Integration of Rs 13,600 Cr BSV acquisition above market expectations. Additionally: Promoter sell-down creating supply overhang perception. Review the full risk analysis section for details.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Mankind_Pharmas_market_cap_and_PE\"><\/span><strong>Q: What is Mankind Pharma&#8217;s market cap and P\/E?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Mankind Pharma has market cap of Rs 74,000 Cr and trailing P\/E of 42x at Rs 1,850. 52-week range is Rs 1,650 to Rs 2,800.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_are_Mankind_Pharmas_growth_catalysts\"><\/span><strong>Q: What are Mankind Pharma&#8217;s growth catalysts?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Three key catalysts: BSV Group Acquisition Synergies, Consumer OTC Brand Portfolio, and India Branded Generic Volume Growth.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Mankind_Pharmas_long-term_target\"><\/span><strong>Q: What is Mankind Pharma&#8217;s long-term target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Mankind Pharma long-term share price target for FY27\u201328 is Rs 3,000 in the bull case \u2014 assuming consistent earnings delivery and full catalyst materialisation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Where_can_I_track_Mankind_Pharma_live\"><\/span><strong>Q: Where can I track Mankind Pharma live?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Track Mankind Pharma (NSE: MANKIND) live on the Univest Screener at univest.in\/screeners. Download the Univest App for real-time alerts and SEBI-registered research.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Articles\"><\/span><strong>Recent Articles<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/why-raymonds-share-price-falling\">Why is Raymond\u2019s Share Price Falling?<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-gacm-technologies-share-price-falling\">Why is the GACM Technologies Share Price Falling?<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-regaal-resources-share-price-falling\">Why is Regaal Resources Share Price Falling?<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-mangalore-refinery-petrochemicals-share-price-falling\">Why is Mangalore Refinery &amp; Petrochemicals (MRPL) Share Price Falling?<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-all-time-plastics-share-price-falling\">Why is All Time Plastics Share Price Falling?<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Mankind Pharma (NSE: MANKIND) trades at Rs 1,850 as of April 2026 \u2014 against a 52-week high of Rs 2,800 and a 52-week low of Rs 1,650. The analyst consensus 12-month Mankind Pharma share price target is Rs 2,200\u20132,500, implying 19\u201335% upside. This article covers the key catalysts, risks, financial positioning, and a structured bull\/bear<\/p>\n","protected":false},"author":26,"featured_media":71726,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-71725","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"_edit_lock":["1776241229:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["842"],"rank_math_seo_score":["77"],"rank_math_focus_keyword":["Mankind Pharma"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Mankind Pharma Share Price Target 2026: Analyst Forecast, Bull &amp; Bear"],"rank_math_description":["Mankind Pharma (NSE: MANKIND) share price target 2026 \u2014 analyst consensus Rs 2,200\u20132,500. CMP Rs 1,850, bull case Rs 3,000, bear case Rs 1,400. 19\u201335% upside. Full analysis \n"],"_thumbnail_id":["71726"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8173"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/15134403\/Mankind-Pharma-Share-Price-Target-1.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/71725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=71725"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/71725\/revisions"}],"predecessor-version":[{"id":71727,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/71725\/revisions\/71727"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/71726"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=71725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=71725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=71725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}